Magnetocardiography as a Non-Invasive Tool for Detecting Tissue Rejection

Status Completed

Clinical Trial Summary

Heart transplantation is a great procedure for selected patients with end-stage heart failure, but graft rejection remains a major factor limiting long-term survival despite continued advancement in the scientific skill of immunosuppression. The only reliable method used today to detect rejection is doing repeated biopsy of the heart. This is expensive, invasive, inconvenient to the patient, and associated with a significant risk of serious complications, as a piece directly from the inner surface of the patients heart is needed. The magnetocardiograph (MCG) device is an invention that may provide new means to assess changes in the heart tissue, as it may detect small changes that happen in the heart cells when they are undergoing rejection.

Clinical Trial Description

Heart transplantation is an advantageous procedure for selected patients with end-stage heart failure. Graft rejection remains a major factor limiting long-term survival despite continued advancement in the scientific skill of immunosuppression. Hyperacute rejection occurs rarely since screening of recipient for anti-donor antibodies was introduced. Focal or diffuse acute cellular rejection is diagnosed by endomyocardial biopsy (EMB). Coronary angiography (CA) is used to monitor for allograft arteriopathy, also described as chronic rejection. Repeated endomyocardial biopsy (EMB) remains the only surveillance method available. Endomyocardial biopsy is expensive, invasive, inconvenient to the patient, and associated with a significant incidence of serious complications. The MCG device is an invention that may provide a sensitive and objective means to assess alterations in the heart tissue. Because the acute inflammatory process of rejection deleteriously affects myocyte structure and function, we hypothesize that either or both the de- and re-polarization changes will occur in the cardiac cycle with subsequent changes in the cardiac magnetic fields and may give altered readings in the affected patient over time. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Heart Transplantation

Clinical Trial Details

NCT number	NCT00169936
Study type	Interventional
Source	Mayo Clinic
Contact
Status	Completed
Phase	Phase 3
Start date	December 2004
Completion date	January 2007

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06035991` - First Clinical Evaluation of Heart Transplantation With Grafts Preserved Using an Ex-vivo Extended Perfusion System	N/A
Recruiting	`NCT01927614` - Advanced Cardiac Imaging in Cardiac Allograft Vasculopathy	N/A
Recruiting	`NCT01705015` - Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement	N/A
Completed	`NCT01655563` - Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation	Phase 2
Completed	`NCT01028599` - Effect of Physical Training on Oxygen Uptake and Endothelial Function in Heart Transplant Recipients	N/A
Completed	`NCT00531921` - Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival	N/A
Terminated	`NCT00420537` - Shift to Everolimus (RAD) Kidney Sparing Study	Phase 4
Enrolling by invitation	`NCT03292861` - The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients	Phase 2
Recruiting	`NCT04924491` - Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children	Phase 1/Phase 2
Recruiting	`NCT05270902` - Haemoadsorption During Heart Transplantation	N/A
Completed	`NCT05289180` - Brachial Right Ventricle - Endomyocardial Biopsy
Recruiting	`NCT03687723` - Observational Study of the Clinical Use of the OCS™ Heart
Completed	`NCT01091194` - Effect of Exercise After Heart Transplantation	Phase 2
Completed	`NCT01182571` - Exploration of Fatigue, Uncertainty, Depression and Quality of Life in Heart Transplantation Recipients	N/A
Terminated	`NCT00678002` - Quality of Life in Pediatric Transplant Patients
Withdrawn	`NCT00780637` - Brachial Artery t-PA Release in Heart Transplant Recipients	N/A
Withdrawn	`NCT00780377` - Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients	N/A
Withdrawn	`NCT00572286` - Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study	N/A
Terminated	`NCT00121784` - Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients	Phase 4
Completed	`NCT00690157` - Registry of Patients Referred for Heart Transplantation	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Magnetocardiography as a Non-Invasive Tool for Detecting Tissue Rejection in Heart Transplant Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms